Wondamox-CV 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg, Clavulanic Acid 125 mg, and Lactobacillus 60 million spores, designed to treat a broad spectrum of bacterial infections. Amoxycillin, a beta-lactam antibiotic, acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid serves as a beta-lactamase inhibitor, preventing enzymatic degradation of amoxycillin by beta-lactamase-producing bacteria, thereby extending its antibacterial efficacy. The inclusion of Lactobacillus spores helps restore and maintain normal intestinal flora, reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Wondamox-CV 625 is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other susceptible bacterial infections. It is particularly useful in infections caused by beta-lactamase-producing strains. The combination should be used as prescribed, with attention to dosage and duration to minimize resistance development. Contraindications include hypersensitivity to penicillins, cephalosporins, or any component of the formulation. Caution is advised in patients with a history of liver dysfunction. Common adverse effects may include gastrointestinal discomfort, nausea, and rash. Wondamox-CV 625 Tablet offers an effective therapeutic option combining antimicrobial potency with gut flora protection.